- Conditions
- Suicide, Psychosis
- Interventions
- Cognitive Behavioral Suicide Prevention for psychosis (CBSPp), Services as Usual (SAU)
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 649–672
of 719
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lung Cancer
- Interventions
- Cemiplimab, Kevzara (Sarilumab)
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Systemic Juvenile Idiopathic Arthritis
- Interventions
- rilonacept (IL-1 Trap), Placebo
- Drug · Other
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 4 Years to 20 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Wilmington, Delaware • Chicago, Illinois + 6 more
- Conditions
- Ovarian Cancer, Triple-negative Breast Cancer, Urothelial Carcinoma, Solid Tumor
- Interventions
- Rucaparib, Lucitanib, Sacituzumab govitecan
- Drug
- Lead sponsor
- pharmaand GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Nashville, Tennessee • Houston, Texas
- Conditions
- Chronic Myeloproliferative Disorders
- Interventions
- imatinib mesylate
- Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Postbariatric Hypoglycemia
- Interventions
- MBX 1416 (INN imapextide)
- Drug
- Lead sponsor
- MBX Biosciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Morehead City, North Carolina • Knoxville, Tennessee + 1 more
- Conditions
- Chronic Sinusitis With Nasal Polyps and Eosinophilia
- Interventions
- dexpramipexole
- Drug
- Lead sponsor
- Knopp Biosciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 7
- States / cities
- Boca Raton, Florida • Baltimore, Maryland • Boston, Massachusetts + 4 more
- Conditions
- Parkinson's Disease
- Interventions
- piclozotan, 0.9% sodium chloride (normal saline)
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 5
- States / cities
- Fountain Valley, California • Tampa, Florida • Atlanta, Georgia + 2 more
- Conditions
- Developmental Delay
- Interventions
- Playgroup
- Behavioral
- Lead sponsor
- Florida Gulf Coast University
- Other
- Eligibility
- 15 Months to 5 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Fort Myers, Florida
- Conditions
- Glioblastoma
- Interventions
- ITI-1001
- Drug
- Lead sponsor
- Immunomic Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hypertension, Cardiovascular Diseases
- Interventions
- Vinyasa Yoga
- Behavioral
- Lead sponsor
- West Virginia University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Degenerative Disc Disease, Spondylolisthesis
- Interventions
- Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules, Iliac crest autograft
- Device · Other
- Lead sponsor
- BioSurface Engineering Technologies, Inc
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 6
- States / cities
- Durango, Colorado • Washington D.C., District of Columbia • Kansas City, Kansas + 3 more
- Conditions
- Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
- Interventions
- BNT327 Dose Level 1 (DL1), BNT327 Dose Level 1 (DL2), Nab-placlitaxel, Carboplatin, Gemcitabine, Paclitaxel, Eribulin, BNT327 Optimized Dose, BNT327 Equivalent Q3W Dose
- Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 13
- States / cities
- Beverly Hills, California • Los Angeles, California • Palo Alto, California + 10 more
- Conditions
- Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Interventions
- Lanraplenib, Gilteritinib
- Drug
- Lead sponsor
- Kronos Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 5 more
- Conditions
- Metastatic Melanoma, Liver Metastases
- Interventions
- Nivolumab and Relatlimab, Melphalan
- Drug · Device
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Multiple Myeloma
- Interventions
- ABBV-438
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 7
- States / cities
- Duarte, California • Irvine, California • Denver, Colorado + 4 more
- Conditions
- Sepsis, Septic Shock
- Interventions
- Thoracic duct drainage
- Procedure
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Breast Cancer
- Interventions
- BTX-9341, Fulvestrant
- Drug
- Lead sponsor
- Biotheryx, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 6
- States / cities
- Rochester, Minnesota • Omaha, Nebraska • Houston, Texas + 3 more
- Conditions
- Chronic Hepatitis C Infection, Genotype 1
- Interventions
- recombinant variant of interferon-alpha 2b, Peginterferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- HanAll BioPharma Co., Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 6
- States / cities
- Los Angeles, California • National City, California • Miami, Florida + 3 more
- Conditions
- Immune System Disorder
- Interventions
- Isatuximab SAR650984, Acetaminophen (paracetamol) or equivalent, Ranitidine or equivalent, Diphenhydramine or equivalent, Methylprednisolone or equivalent, Montelukast or equivalent
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 4
- States / cities
- San Francisco, California • Rochester, Minnesota • New York, New York + 1 more
- Conditions
- Smoking Cessation
- Interventions
- WeChat Quit Coach, Leaflet, Optional Nicotine Replacement Therapy (NRT) Patches or Lozenges
- Behavioral · Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- EGFR Inhibitor Induced Acneiform Lesions
- Interventions
- LUT014
- Drug
- Lead sponsor
- Lutris Pharma Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 4
- States / cities
- Los Angeles, California • St Louis, Missouri • New York, New York + 1 more
- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- Latanoprost-PPDS
- Drug
- Lead sponsor
- Mati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 8
- States / cities
- Artesia, California • Sacramento, California • Bel Air, Maryland + 5 more
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- Dasatinib, Nivolumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Dallas, Texas + 2 more